Shots:

• The US FDA has approved Oncomine Dx Target Test as a CDx to identify EGFR exon 20 insertion mutations in patients with NSCLC who undergo treatment with amivantamab
• The approval allows clinicians to use FFPE tissue samples to identify patients in the US. The test can assess 23 genes that are associated with NSCLC & are currently approved in 15+ countries including the US, EU, Japan, South Korea & Middle East
• The approval marks 2nd indication for Oncomine Dx Target Test as a CDx for patients with EGFR exon 20 insertion mutations. The test is 1st FDA-approved NGS CDx that is used on FFPE tissue to identify patients for treatment with amivantamab who have progressed on or after Pt-based CT

 Ref: PR Newswire | Image: Thermo Fisher